Cargando…

Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors

BACKGROUND: The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria are the gold standard for risk‐stratifying patients with metastatic renal cell cancer (mRCC). We developed a novel risk scoring system for patients with mRCC treated with immune checkpoint inhibitors (I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martini, Dylan J., Liu, Yuan, Shabto, Julie M., Carthon, Bradley C., Hitron, Emilie Elise, Russler, Greta Anne, Caulfield, Sarah, Kissick, Haydn T., Harris, Wayne B., Kucuk, Omer, Master, Viraj A., Bilen, Mehmet Asim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2019
Materias:	Genitourinary Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066702/ https://www.ncbi.nlm.nih.gov/pubmed/32162798 http://dx.doi.org/10.1634/theoncologist.2019-0578

Ejemplares similares

Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors
por: Shabto, Julie M., et al.
Publicado: (2020)

Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors
por: Brown, Jacqueline T, et al.
Publicado: (2021)

Blood-Based Next-Generation Sequencing in Adrenocortical Carcinoma
por: Nazha, Bassel, et al.
Publicado: (2022)

Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
por: Zhuang, Tony Z, et al.
Publicado: (2022)

Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University Experience
por: Martini, Dylan J., et al.
Publicado: (2022)

Body Composition Variables as Radiographic Biomarkers of Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors
por: Martini, Dylan J., et al.
Publicado: (2021)

Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint Blockade
por: Olsen, T. Anders, et al.
Publicado: (2021)

Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas
por: Alhalabi, Omar, et al.
Publicado: (2023)

Metastatic Prostate Cancer Manifesting as Cholestatic Jaundice: A Case Report and Review of the Literature
por: Ravindranathan, Deepak, et al.
Publicado: (2018)

Ramucirumab and Docetaxel in Patients with Metastatic Urothelial Carcinoma Harboring Fibroblast Growth Factor Receptor Alterations: A Case Series and Literature Review
por: Smith, Katherine Emilie Rhoades, et al.
Publicado: (2020)

Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas
por: Thouvenin, Jonathan, et al.
Publicado: (2022)

Neoadjuvant Cabozantinib in an Unresectable Locally Advanced Renal Cell Carcinoma Patient Leads to Downsizing of Tumor Enabling Surgical Resection: A Case Report
por: Bilen, Mehmet A., et al.
Publicado: (2021)

Clinical and Economic Outcomes in Patients With Metastatic Urothelial Carcinoma Receiving First-Line Systemic Treatment (the IMPACT UC I Study)
por: Bilen, Mehmet A, et al.
Publicado: (2023)

Case Report: Exceptional Response to Nivolumab Plus Ipilimumab in a Young Woman With TFE3-SFPQ Fusion Translocation-Associated Renal Cell Carcinoma
por: Martini, Dylan J., et al.
Publicado: (2021)

Durable complete response for oligometastatic renal cell carcinoma with immune checkpoint inhibition and cytoreductive nephrectomy in a Jehovah’s witness: A case report
por: Zhuang, Tony Zibo, et al.
Publicado: (2022)

Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy
por: Olsen, T. Anders, et al.
Publicado: (2022)

Computed Tomography Texture Analysis for Predicting Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors
por: Park, Hyo Jung, et al.
Publicado: (2022)

Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer
por: Freeman, Meredith N, et al.
Publicado: (2022)

Patients’ Perceptions Regarding the Relevance of Items Contained in the Functional Assessment of Cancer Therapy Kidney Symptom Index-19
por: Bergerot, Cristiane Decat, et al.
Publicado: (2023)

Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy
por: Bilen, Mehmet Asim, et al.
Publicado: (2019)

Metastatic Clear-Cell Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors: Therapies and Ongoing Trials
por: Zhuang, Tony Zibo, et al.
Publicado: (2022)

Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma
por: McGregor, Bradley, et al.
Publicado: (2023)

Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood
por: Carlisle, Jennifer Wilkinson, et al.
Publicado: (2022)

Percutaneous Image-Guided Nodal Biopsy After 11C-Choline PET/CT for Biochemically Recurrent Prostate Cancer: Imaging Predictors of Disease and Clinical Implications
por: Welch, Brian T., et al.
Publicado: (2018)

(11)C-Choline PET Guided Salvage Radiation Therapy for Isolated Pelvic and Paraortic Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Rationale and Early Genitourinary or Gastrointestinal Toxicities
por: Jethwa, Krishan R., et al.
Publicado: (2019)

Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer
por: Antonarakis, Emmanuel S., et al.
Publicado: (2016)

Stereotactic body radiation therapy for medically inoperable, clinically localized, urothelial carcinoma of the renal pelvis: A case report
por: Evans, Jaden D., et al.
Publicado: (2017)

Salvage image guided radiation therapy to the prostate after cryotherapy failure
por: Hopper, Austin B., et al.
Publicado: (2017)

Late toxicity after post-prostatectomy intensity modulated radiation therapy: Evaluating normal-tissue sparing guidelines
por: Akthar, Adil S., et al.
Publicado: (2018)

Initial toxicity, quality-of-life outcomes, and dosimetric impact in a randomized phase 3 trial of hypofractionated versus standard fractionated proton therapy for low-risk prostate cancer
por: Vargas, Carlos E., et al.
Publicado: (2018)

Radiomics-guided therapy for bladder cancer: Using an optimal biomarker approach to determine extent of bladder cancer invasion from t2-weighted magnetic resonance images
por: Tong, Yubing, et al.
Publicado: (2018)

Prostate Stereotactic Body Radiation Therapy With a Focal Simultaneous Integrated Boost: Acute Toxicity and Dosimetry Results From a Prospective Trial
por: McDonald, Andrew M., et al.
Publicado: (2018)

Transitioning From a Low-Dose-Rate to a High-Dose-Rate Prostate Brachytherapy Program: Comparing Initial Dosimetry and Improving Workflow Efficiency Through Targeted Interventions
por: Solanki, Abhishek A., et al.
Publicado: (2018)

The Perineural Invasion Paradox: Is Perineural Invasion an Independent Prognostic Indicator of Biochemical Recurrence Risk in Patients With pT2N0R0 Prostate Cancer? A Multi-Institutional Study
por: Kraus, Ryan Douglas, et al.
Publicado: (2018)

Analysis of Gastrointestinal Toxicity in Patients Receiving Proton Beam Therapy for Prostate Cancer: A Single-Institution Experience
por: Lee, Howard J., et al.
Publicado: (2018)

Radiation-related Lymphopenia after Pelvic Nodal Irradiation for Prostate Cancer
por: Schad, Michael D., et al.
Publicado: (2019)

Early Tolerance Outcomes of Stereotactic Hypofractionated Accelerated Radiation Therapy Concomitant with Pelvic Node Irradiation in High-risk Prostate Cancer
por: Pinitpatcharalert, Attapol, et al.
Publicado: (2019)

Regional Differences in the Treatment of Localized Prostate Cancer: An Analysis of Surgery and Radiation Utilization in the United States
por: Scherzer, Nickolas D., et al.
Publicado: (2019)

Dose-Escalated Intensity Modulated Radiation Therapy for Prostate Cancer: 15-Year Outcomes Data
por: Weg, Emily S., et al.
Publicado: (2019)

Pathologic Complete Response After Chemoradiation of a Massive Primary Urethral Carcinoma
por: Singh, Tanmay, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_67mh4icmqk0kbin3tsevml278f